库司特森联合多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌患者(SYNERGY试验):一项3期、多中心、开放标签、随机试验
SYNERGY是一项3期、多中心、开放标签、随机试验,纳入1022例未接受过化疗的转移性去势抵抗性前列腺癌患者,随机接受多西他赛+泼尼松+库司特森或多西他赛+泼尼松。两组中位总生存期分别为23.4个月和22.0个月,无显著差异(HR 0.93,95%CI 0.79-1.10,P=0.415)。联合库司特森耐受性尚可,但未显著延长总生存期。
要点
- 库司特森联合多西他赛和泼尼松未显著改善转移性去势抵抗性前列腺癌患者的总生存期。
- 联合组中性粒细胞减少(3级13% vs 6%;4级20% vs 15%)和发热性中性粒细胞减少(3级10% vs 6%)发生率高于单纯化疗组。
- 联合组严重不良事件发生率为43%(214/501),单纯化疗组为36%(181/499)。
核心结论
- 在转移性去势抵抗性前列腺癌患者中,一线多西他赛和泼尼松联合库司特森耐受性尚可,但联合组总生存期未显著长于单纯多西他赛和泼尼松组。
研究设计与样本
- SYNERGY为3期、多中心、开放标签、随机试验,在12个国家的134个研究中心开展。
- 纳入标准:转移性去势抵抗性前列腺癌、未接受过化疗、前列腺特异性抗原大于5 ng/mL、卡氏功能状态评分70%或以上。
- 患者按1:1随机分配至多西他赛+泼尼松+库司特森组或多西他赛+泼尼松组,随机分层因素为癌症相关疼痛的阿片类药物使用和影像学进展证据。
- 所有患者接受多西他赛75 mg/m2静脉给药,泼尼松5 mg口服每日两次;联合组另接受库司特森640 mg静脉给药,在三次640 mg负荷剂量后每周一次。
- 主要终点为总生存期,在意向治疗人群中分析;安全性分析集为至少接受一次研究剂量的患者。
主要发现
- 2010年12月10日至2012年11月7日共入组1022例患者,其中510例分配至多西他赛+泼尼松+库司特森组,512例分配至多西他赛+泼尼松组。
- 两组中位总生存期分别为23.4个月(95%CI 20.9-24.8)和22.0个月(95%CI 19.5-24.0),HR 0.93(95%CI 0.79-1.10),P=0.415。
- 3级或以上最常见不良事件(联合组n=501 vs 单纯化疗组n=499):中性粒细胞减少(3级63例[13%] vs 28例[6%];4级98例[20%] vs 77例[15%])、发热性中性粒细胞减少(3级52例[10%] vs 31例[6%];4级4例[1%] vs 2例[<1%])、乏力(3级53例[11%] vs 41例[8%];4级3例[1%] vs 1例[<1%])。
- 严重不良事件:联合组214/501例(43%),单纯化疗组181/499例(36%)。
- 归因于不良事件的死亡:联合组23例(5%),单纯化疗组24例(5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as chemotherapy. Custirsen is a second-generation antisense oligonucleotide that inhibits clusterin production. The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer. METHODS: SYNERGY was a phase 3, multicentre, open-label, randomised trial set at 134 study centres in 12 countries. Patients were eligible for participation if they had: metastatic castration-resistant prostate cancer and had received no previous chemotherapy; prostate-specific antigen greater than 5 ng/mL; and a Karnofsky performance score of 70% or higher. Patients were randomly assigned 1:1 centrally to either the docetaxel, prednisone, and custirsen combination or docetaxel and prednisone alone. Patients were not masked to treatment allocation. Randomisation was stratified by opioid use for cancer-related pain and radiographic evidence of progression. All patients received docetaxel 75 mg/m2 intravenously with 5 mg of prednisone orally twice daily. Patients assigned docetaxel, prednisone, and custirsen received weekly doses of custirsen 640 mg intravenously after three loading doses of 640 mg. The primary endpoint was overall survival analysed in the intention-to-treat population. Patients who received at least one study dose were included in the safety analysis set. This trial is registered with ClinicalTrials.gov, number NCT01188187. The trial is completed and final analyses are reported here. FINDINGS: Between Dec 10, 2010, and Nov 7, 2012, 1022 patients were enrolled to the trial, of whom 510 were assigned docetaxel, prednisone, and custirsen and 512 were allocated docetaxel and prednisone. No difference in overall survival was recorded between the two groups (median survival 23·4 months [95% CI 20·9-24·8] with docetaxel, prednisone, and custirsen vs 22·0 months [19·5-24·0] with docetaxel and prednisone; hazard ratio [HR] 0·93, 95% CI 0·79-1·10; p=0·415). The most common adverse events of grade 3 or worse in the docetaxel, prednisone and custirsen group (n=501) compared with the docetaxel and prednisone alone group (n=499) were neutropenia (grade 3, 63 [13%] vs 28 [6%]; grade 4, 98 [20%] vs 77 [15%]), febrile neutropenia (grade 3, 52 [10%] vs 31 [6%]; grade 4, four [1%] vs two [<1%]), and fatigue (grade 3, 53 [11%] vs 41 [8%]; grade 4, three [1%] vs one [<1%]). One or more serious adverse events were reported for 214 (43%) of 501 patients treated with docetaxel, prednisone, and custirsen and 181 (36%) of 499 receiving docetaxel and prednisone alone. Adverse events were attributable to 23 (5%) deaths in the docetaxel, prednisone, and custirsen group and 24 (5%) deaths in the docetaxel and prednisone alone group. INTERPRETATION: Addition of custirsen to first-line docetaxel and prednisone was reasonably well tolerated, but overall survival was not significantly longer for patients with metastatic castration-resistant prostate cancer treated with this combination, compared with patients treated with docetaxel and prednisone alone. FUNDING: OncoGenex Technologies.
引用
- Chi KN, Higano CS, Blumenstein B, et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017. PMID: 28283282. doi:10.1016/S1470-2045(17)30168-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。